Literature DB >> 27069332

Relationship Between Hemodynamically Significant Ductus Arteriosus and Ischemia-Modified Albumin in Premature Infants.

Hasan Kahveci1, Cüneyt Tayman2, Fuat Laloğlu3, Nazan Kavas3, Murat Ciftel4, Osman Yılmaz4, Esra Laloğlu5, Abdulah Erdil3, Hülya Aksoy5, Salih Aydemir6.   

Abstract

Hemodynamically significant ductus arteriosus (hsPDA) may alter organ perfusion by interfering blood flow to the tissues. Therefore, in infants with hsPDA, hypoxia occurs in many tissues. In this study, we aimed to investigate the diagnostic significance of serum (ischemia-modified albumin) IMA levels as a screening tool for hsPDA, and its relation to the severity of the disease in the preterm neonates. For this purpose, seventy-two premature infants with gestation age <34 weeks were included in the study. Thirty premature infants with hsPDA were assigned as the study group and 42 premature infants without PDA were determined as the control group. Blood samples were collected before the treatment and 24 h after the treatment, and analyzed for IMA levels. IMA levels in the study group (1.26 ± 0.36 ABSU) were found to be significantly higher than control group (0.65 ± 0.12 ABSU) (p < 0.05). In infants with hsPDA, a positive correlation was found between IMA and PDA diameter (ρ = 0.876, p = 0.022), and LA/Ao ratio (ρ = 0.863, p = 0.014). The cut-off value of IMA for hsPDA was measured as 0.78 ABSU with 88.89 % sensitivity, and 90.24 % specificity, 85.71 % positive predictive, 92.5 % negative predictive value [area under the curve (AUC) = 0.96; p < 0.001]. The mean IMA value of the infants with hsPDA before treatment was 1.26 ± 0.36 ABSU, and the mean IMA value of infants after medical treatment was 0.67 ± 0.27 ABSU (p = 0.03). We concluded that IMA can be used as a marker for the diagnosis and monitoring of a successful treatment of hsPDA.

Entities:  

Keywords:  Diagnosis; Ischemia-modified albumin; Newborn; Patent ductus arteriosus; Preterm

Year:  2015        PMID: 27069332      PMCID: PMC4820428          DOI: 10.1007/s12291-015-0523-z

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  24 in total

1.  Does primary surgical closure of the patent ductus arteriosus in infants <1500 g or ≤32 weeks' gestation reduce the incidence of necrotizing enterocolitis?

Authors:  Wendy H Yee; Jeanne Scotland
Journal:  Paediatr Child Health       Date:  2012-03       Impact factor: 2.253

2.  Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre.

Authors:  Gregory P Moore; Sarah L Lawrence; Gyaandeo Maharajh; Amanda Sumner; Isabelle Gaboury; Nick Barrowman; Brigitte Lemyre
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

3.  Cerebral oxygenation during different treatment strategies for a patent ductus arteriosus.

Authors:  Valerie Y Chock; Chandra Ramamoorthy; Krisa P Van Meurs
Journal:  Neonatology       Date:  2011-06-22       Impact factor: 4.035

Review 4.  Patent ductus arteriosus of the preterm infant.

Authors:  Shannon E G Hamrick; Georg Hansmann
Journal:  Pediatrics       Date:  2010-04-26       Impact factor: 7.124

5.  Cord blood ischemia-modified albumin: is it associated with abnormal Doppler findings in complicated pregnancies and predictive of perinatal asphyxia?

Authors:  Abdullah Kumral; Emre Okyay; Serkan Guclu; Pinar Gencpinar; Gul Huray Islekel; Serife Suna Oguz; Melis Kant; Gamze Demirel; Nuray Duman; Hasan Ozkan
Journal:  J Obstet Gynaecol Res       Date:  2012-12-21       Impact factor: 1.730

6.  Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates.

Authors:  Barbara Amendolia; Madeline Lynn; Vishwanath Bhat; Steven B Ritz; Zubair H Aghai
Journal:  Pediatrics       Date:  2012-04-09       Impact factor: 7.124

Review 7.  Patent ductus arteriosus: patho-physiology, hemodynamic effects and clinical complications.

Authors:  Giovanbattista Capozzi; Giuseppe Santoro
Journal:  J Matern Fetal Neonatal Med       Date:  2011-09-06

Review 8.  Ischemia modified albumin: is this marker of ischemia ready for prime time use?

Authors:  Eftihia Sbarouni; Panagiota Georgiadou; Dimitrios Th Kremastinos; Vasilios Voudris
Journal:  Hellenic J Cardiol       Date:  2008 Jul-Aug

9.  Levels of ischemia-modified albumin in transient tachypnea of the newborn.

Authors:  Osman Oztekın; Salih Kalay; Cuneyt Tayman; Mehmet Namuslu; Hüseyin Tugrul Celık
Journal:  Am J Perinatol       Date:  2014-06-10       Impact factor: 1.862

10.  Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia.

Authors:  David C Gaze
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

View more
  3 in total

1.  Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus.

Authors:  Annemarie Kindler; Barbara Seipolt; Antje Heilmann; Ursula Range; Mario Rüdiger; Sigrun Ruth Hofmann
Journal:  Front Pediatr       Date:  2017-12-22       Impact factor: 3.418

Review 2.  Objective Assessment of Physiologic Alterations Associated With Hemodynamically Significant Patent Ductus Arteriosus in Extremely Premature Neonates.

Authors:  Aparna Patra; Pratibha S Thakkar; Majd Makhoul; Henrietta S Bada
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

3.  Reference Values for Point-of-Care Echocardiographic Measurements of Preterm Infants in China.

Authors:  Dan-Fang Lu; Xiao-Mei Tong; Yun-Feng Liu; Hua Zhang
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.